These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2856529)

  • 21. [Development of HIV vaccines].
    Shibata R
    Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AIDS vaccine development.
    Agosto M; Allan J; Benson C; Berger EA; Blumenthal R; Burton D; Clements J; Coffin J; Connor R; Cullen B; Desrosiers R; Dimitrov D; Doms R; Emerman M; Feinberg M; Fultz P; Gerard C; Gonsalves G; Haase A; Haigwood N; Hirsch V; Ho D; Hoxie JA; Hu SL; Zingale D
    Science; 1998 May; 280(5365):803, 804-5. PubMed ID: 9599148
    [No Abstract]   [Full Text] [Related]  

  • 23. Prospects for a human immunodeficiency virus/AIDS vaccine.
    Murphy FA; Folks TM; Lairmore MD
    Dev Biol Stand; 1990; 72():3-15. PubMed ID: 1704324
    [No Abstract]   [Full Text] [Related]  

  • 24. Thailand weighs AIDS vaccine tests.
    Cohen J
    Science; 1995 Nov; 270(5238):904-7. PubMed ID: 7481784
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS
    Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunology. Bound for glory.
    Cohen J
    Science; 2013 Sep; 341(6151):1168-71. PubMed ID: 24030996
    [No Abstract]   [Full Text] [Related]  

  • 27. Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies.
    Essajee SM; Yogev R; Pollack H; Greenhouse B; Krasinski K; Borkowsky W
    Clin Diagn Lab Immunol; 2002 Jan; 9(1):79-82. PubMed ID: 11777833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIDS vaccines: is older better?
    Cohen J
    Science; 1992 Dec; 258(5090):1880-1. PubMed ID: 1470911
    [No Abstract]   [Full Text] [Related]  

  • 29. Canadian lab to produce HIV immunogen for clinical trials.
    CMAJ; 1990 Nov; 143(9):907. PubMed ID: 2224719
    [No Abstract]   [Full Text] [Related]  

  • 30. gp 120: good, bad or indifferent?
    Steele FR
    Nat Med; 1995 Nov; 1(11):1105-6. PubMed ID: 7584971
    [No Abstract]   [Full Text] [Related]  

  • 31. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
    Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
    J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIDS research. Merck reemerges with a bold AIDS vaccine effort.
    Cohen J
    Science; 2001 Apr; 292(5514):24-5. PubMed ID: 11294193
    [No Abstract]   [Full Text] [Related]  

  • 33. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
    Borkowsky W; Wara D; Fenton T; McNamara J; Kang M; Mofenson L; McFarland E; Cunningham C; Duliege AM; Francis D; Bryson Y; Burchett S; Spector SA; Frenkel LM; Starr S; Van Dyke R; Jimenez E
    J Infect Dis; 2000 Mar; 181(3):890-6. PubMed ID: 10720509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scientific and policy challenges to development of an AIDS vaccine.
    Berkley SF; Koff WC
    Lancet; 2007 Jul; 370(9581):94-101. PubMed ID: 17617277
    [No Abstract]   [Full Text] [Related]  

  • 36. AIDS vaccines. Trials set in high-risk populations.
    Cohen J
    Science; 1992 Dec; 258(5089):1729. PubMed ID: 1465607
    [No Abstract]   [Full Text] [Related]  

  • 37. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
    Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
    Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of the development of an AIDS vaccine.
    Lasky LA
    Crit Rev Immunol; 1989; 9(3):153-72. PubMed ID: 2673294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV vaccines. Viral envelope fails to deliver?
    Bolognesi DP; Matthews TJ
    Nature; 1998 Feb; 391(6668):638-9. PubMed ID: 9490406
    [No Abstract]   [Full Text] [Related]  

  • 40. AIDS vaccines inch closer to useful existence.
    Goldsmith MF
    JAMA; 1991 Mar; 265(11):1356-7. PubMed ID: 1999873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.